Holen Sie sich die Stockscreener-App
11.80
1.91%
-0.23
Schlusskurs vom Vortag:
$12.03
Offen:
$12.03
24-Stunden-Volumen:
259.08K
Relative Volume:
0.82
Marktkapitalisierung:
$233.54M
Einnahmen:
$244.06M
Nettoeinkommen (Verlust:
$87.01M
KGV:
6.4789
EPS:
1.8213
Netto-Cashflow:
$105.95M
1W Leistung:
+4.80%
1M Leistung:
+18.83%
6M Leistung:
-38.54%
1J Leistung:
-18.45%
1-Tages-Spanne:
$11.13
$12.19
1-Wochen-Bereich:
$10.93
$12.19
52-Wochen-Spanne:
$9.69
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
Firmenname
Keros Therapeutics Inc
Sektor
Branche
Telefon
617-314-6297
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
11.80 | 233.54M | 244.06M | 87.01M | 105.95M | 1.8213 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-01-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-13 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-12 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-12 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Eingeleitet | Jefferies | Buy |
| 2024-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-23 | Eingeleitet | Guggenheim | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-21 | Eingeleitet | William Blair | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-31 | Eingeleitet | Wedbush | Outperform |
| 2023-07-26 | Eingeleitet | BofA Securities | Buy |
| 2023-02-14 | Eingeleitet | Cowen | Outperform |
| 2022-10-18 | Eingeleitet | Truist | Buy |
| 2022-07-26 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Discipline and Rules-Based Execution in KROS Response - Stock Traders Daily
KROS Q1 2026 Earnings: EPS Miss of 15.98% as Clinical-Stage Biotech Reports Wider-Than-Expected LossProfit Announcement - dars.gov.et
Keros Therapeutics | DEFA14A: Others - Moomoo
Form 4 Keros Therapeutics Inc For: 6 July By Investing.com - Investing.com Nigeria
Keros Therapeutics (KROS) grants director Anne Prener RSUs and stock options - Stock Titan
Director Anne Prener files Form 3 insider report at Keros Therapeutics (KROS) - Stock Titan
Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors - TipRanks
Behavioral Patterns of KROS and Institutional Flows - Stock Traders Daily
Keros Therapeutics, Inc.(NasdaqGM:KROS) added to Russell Microcap Value Benchmark Index - marketscreener.com
Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 3000E Index - marketscreener.com
Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell Microcap Index - marketscreener.com
Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Value-Defensive Index - marketscreener.com
Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Defensive Index - marketscreener.com
Nurix Therapeutics (NRIX) soars 16.4%: Is further upside left in the stock? - MSN
Keros Therapeutics Inc. (KROS) Stages Strong Rebound, Testing Resistance at $11.54Stock Buy Zone - dars.gov.et
KROS Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBIT forward of Keros Therapeutics, Inc. – NASDAQ:KROS - TradingView
Price to sales forward of Keros Therapeutics, Inc. – NASDAQ:KROS - TradingView
Keros Therapeutics appoints Anne Prener to board of directors - Investing.com
Keros Therapeutics Appoints Anne Prener to Board - TipRanks
Keros Therapeutics appoints Anne Prener to board of directors By Investing.com - Investing.com UK
Anne Prener joins Keros Therapeutics (Nasdaq: KROS) board with equity package - Stock Titan
Keros Therapeutics Appoints Anne Prener to its Board of Directors - GlobeNewswire
Keros Therapeutics Inc (KROS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Keros Therapeutics Inc (KROS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Keros Therapeutics director Nima sells $28,166 in company stock - Investing.com UK
KROS,LBRX Dividends - Finviz
Keros Therapeutics Inc (KROS) Valuation: PE, PB & Fair Value Analysis - TradingKey
(KROS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Madison Avenue Partners LP Reduces Stock Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics Inc (KROS) Institutional Confidence - TradingKey
Keros Therapeutics Inc (KROS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Keros Therapeutics Inc (KROS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insider Buying: Jean Bienaime Acquires Additional Shares of Keros Therapeutics Inc (KROS) - GuruFocus
Keros Therapeutics Inc (KROS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Keros Therapeutics Inc (KROS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Keros Therapeutics (NASDAQ: KROS) director buys 1,000 shares under 10b5-1 plan - Stock Titan
Keros Therapeutics Inc (KROS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Insider Sell: Charles Newton Sells Shares of Keros Therapeutics Inc (KROS) - GuruFocus
Keros Therapeutics director Charles W. Newton sells $5,521 in shares - Investing.com
Keros Therapeutics director Charles W. Newton sells $5,521 in shares By Investing.com - Investing.com Nigeria
Keros Therapeutics Hits 52-Week Low at $9.69 Amidst Major Decline - Markets Mojo
Keros Therapeutics (KROS) director Newton sells 550 shares in planned trade - Stock Titan
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 99% Upside - TradingView
KROS Q1 2026 Earnings: Wider-Than-Expected Loss as Pipeline AdvancesNon-GAAP Earnings - newsline.com
[144] Keros Therapeutics, Inc. SEC Filing - Stock Titan
Keros Therapeutics director Nima sells $28,166 in company stock By Investing.com - Investing.com Nigeria
KROS: KER-065 targets muscle regeneration in DMD, with strong early data and a solid financial runway - TradingView
Director at Keros Therapeutics (NASDAQ: KROS) logs 2,625-share sale - Stock Titan
Director at Keros Therapeutics (KROS) sells 2,625 shares in Rule 10b5-1 trade - Stock Titan
Keros Therapeutics (KROS) Faces Selling Pressure as Shares Approach Key SupportATR Trailing Stop - newsline.com
Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):